Evropa Ittifoqi birinchi COVID-19 tabletkasini tasdiqladi
Evropa Ittifoqi birinchi COVID-19 tabletkasini tasdiqladi

The European Medicines Agency (EMA) has announced that it has issued the conditional authorization (CMA) for Pfizer’s oral coronavirus treatment, Paxlovid.

Virusning davom etayotgan tarqalishi fonida Omikron torting Evropa, EMA birinchi koronavirusni davolash tabletkasi "qo'shimcha kislorodga muhtoj bo'lmagan va kasallikning og'irlashishi xavfi yuqori bo'lgan kattalardagi COVID-19 ni davolash uchun" tavsiya etilganini aytdi.

CMA mexanizmi, EMAning ta'kidlashicha, "sog'liqni saqlash sohasidagi favqulodda vaziyatlarda" dori-darmonlarni avtorizatsiya qilish jarayonini tezlashtirish uchun ishlatiladi.

Evropa regulyatorining roziligi bilan, Paxlovid da tavsiya etilgan og'iz orqali yuboriladigan birinchi antiviral dori bo'ldi EU COVID-19 ni davolash uchun.

Tasdiqlanishi Paxlovid follows the authorization in December of antibody treatment Xevudy, produced by GlaxoSmithKline and Vir Biotechnology, as well as Kineret by Swedish Sobi, which was originally an arthritis drug but is able to “reduce” COVID-related inflammation.

Paxlovidning raqobatchisi Merck's Lagevrio (molnupiravir) EMA tomonidan ko'rib chiqilmoqda, chunki uning samaradorligi kutilganidan pastroq ekanligi isbotlangan.

Paxlovid ham, molnupiravir ham o'tgan yilning dekabr oyida AQSh oziq-ovqat va farmatsevtika idorasidan ruxsat oldi.

 

Chop etish uchun do'st, PDF & Email

Tegishli yangiliklar